NASDAQ: GILD - Gilead Sciences

Yield per half year: +21.95%
Dividend yield: +3.64%
Sector: Healthcare

Share chart Gilead Sciences

Extended chart Simple chart
Financial Markets by TradingView

About Gilead Sciences

Gilead Sciences, Inc., биофармацевтическая компания, основанная на исследованиях, обнаруживает, разрабатывает и продает лекарства для удовлетворения неудовлетворенных медицинских потребностей в США, Европе и на международном уровне. Компания предоставляет продукты Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera / Eviplera, Stribild и Atripla для лечения инфекции, вызванной вирусом иммунодефицита человека (ВИЧ); Веклуры, инъекция для внутривенного введения, для лечения коронавирусной болезни 2019; и Epclusa, Harvoni, Vosevi, Vemlidy и Viread для лечения заболеваний печени.

more details
Он также предлагает продукты Yescarta, Tecartus, Trodelvy и Zydelig для лечения гематологических, онкологических пациентов и пациентов с клеточной терапией. Кроме того, компания предлагает Letairis, пероральный препарат для лечения легочной артериальной гипертензии; Ранекса, пероральный препарат для лечения хронической стенокардии; и AmBisome, липосомальный состав для лечения серьезных инвазивных грибковых инфекций. Gilead Sciences, Inc. имеет соглашения о сотрудничестве с Arcus Biosciences, Inc.; Пионырь; Тизона; Tango Therapeutics, Inc .; Jounce Therapeutics, Inc .; Галапагосские острова; Янссен; Japan Tobacco, Inc.; Гадета; Bristol-Myers Squibb Company; Мерк; и Ново Нордиск А / С. Компания была основана в 1987 году, ее штаб-квартира находится в Фостер-Сити, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1992-01-22
ISIN US3755581036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 2.69
Дивиденд ао 3.1
Сайт http://www.gilead.com
Цена ао 106.5
Change price per day: +0.8246% (105.51)
Change price per week: +0.6624% (105.68)
Change price per month: -0.6537% (107.08)
Change price per 3 month: +14.44% (92.96)
Change price per half year: +21.95% (87.23)
Change price per year: +58.71% (67.03)
Change price per 3 year: +68.27% (63.22)
Change price per 5 year: +56.67% (67.9)
Change price per 10 year: +32.3% (80.41)
Change price per year to date: +15.62% (92.01)
All parameters

Underestimation

Title Value Grade
P/S 4.02 4
P/BV 6 2
P/E 240.57 1
EV/EBITDA 65.34 1
Total: 5.63

Efficiency

Title Value Grade
ROA, % 0.7926 1
ROE, % 2.28 1
Total: 2

Dividends

Title Value Grade
Div yield, % 3.64 9.1
DSI 0.9286 9.29
Total: 6.5

Debt

Title Value Grade
Debt/EBITDA 1.87 7
Total: 6.6

Growth impulse

Title Value Grade
Yield Revenue, % 16.46 3
Yield Ebitda, % -80.47 0
Yield EPS, % 442.51 10
Total: 5.6
More

Dividend, % Dividend Result of period Buy before Register closing date Payment before
2.87% 3.097 IV кв. 2024 12.03.2025 14.03.2025 31.03.2025
3.42% 3.076 III кв. 2024 11.12.2024 13.12.2024 30.12.2024
1.05% 0.77 II кв. 2024 11.09.2024 13.09.2024 30.09.2024
1.05% 0.77 I кв. 2024 12.06.2024 14.06.2024 01.07.2024
1.06% 0.77 IV кв. 2023 12.03.2024 14.03.2024 29.03.2024
0.92% 0.75 III кв. 2023 12.12.2023 14.12.2023 29.12.2023
0.98% 0.75 II кв. 2023 12.09.2023 14.09.2023 29.09.2023
0.89% 0.75 IV кв. 2022 10.03.2023 14.03.2023 29.03.2023
0.83% 0.73 III кв. 2022 12.12.2022 14.12.2022 29.12.2022
1.14% 0.73 II кв. 2022 12.09.2022 14.09.2022 29.09.2022
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
15.04.2025 16.04.2025 Dickinson Andrew D
Chief Financial Officer		 Sale 106.4 266 000 2500 0 0 link
15.04.2025 15.04.2025 ANDREW DICKINSON
Officer		 Purchase 106.4 266 000 2500 0 0 link
12.02.2025 13.02.2025 Dickinson Andrew D
Chief Financial Officer		 Sale 102.22 14 073 200 137676 0 -0.01 link
12.02.2025 13.02.2025 Dickinson Andrew D
Chief Financial Officer		 Purchase 67.27 9 261 460 137676 0 0.01 link
31.01.2025 03.02.2025 Dickinson Andrew D
Chief Financial Officer		 Sale 97.22 13 822 700 142180 0 -0.01 link
31.01.2025 03.02.2025 Dickinson Andrew D
Chief Financial Officer		 Purchase 67.52 9 599 990 142180 0 0.01 link
31.01.2025 31.01.2025 MERDAD V PARSEY
Officer		 Purchase 98 18 098 900 184683 0 0.01 link
15.01.2025 16.01.2025 Dickinson Andrew D
Chief Financial Officer		 Sale 91.35 228 375 2500 0 0 link
19.12.2024 23.12.2024 GILEAD SCIENCES, INC.
10% Owner		 Purchase 21.37 20 098 500 940499 0 0.08 link
29.11.2024 03.12.2024 Dickinson Andrew D
Chief Financial Officer		 Sale 92.76 23 064 300 248645 0 -0.02 link
29.11.2024 03.12.2024 Dickinson Andrew D
Chief Financial Officer		 Purchase 70.5 17 529 500 248645 0 0.02 link
29.11.2024 29.11.2024 ANDREW DICKINSON
Officer		 Purchase 92.76 23 064 300 248645 0 0.02 link
27.11.2024 29.11.2024 Parsey Merdad
Chief Medical Officer		 Sale 91.92 15 094 300 164211 0 -0.01 link
27.11.2024 29.11.2024 Parsey Merdad
Chief Medical Officer		 Purchase 62.44 9 079 590 145413 0 0.01 link
12.09.2024 13.09.2024 Parsey Merdad
Chief Medical Officer		 Sale 84.5 1 795 290 21246 0 0 link
12.09.2024 13.09.2024 Parsey Merdad
Chief Medical Officer		 Purchase 57.92 1 448 000 25000 0 0 link
12.09.2024 13.09.2024 Mercier Johanna
Chief Commercial Officer		 Sale 83.78 2 459 530 29357 0 0 link
01.07.2024 01.07.2024 Parsey Merdad
Chief Medical Officer		 Sale 68.63 137 260 2000 0 0 link
29.02.2024 29.02.2024 Parsey Merdad
Chief Medical Officer		 Sale 72.74 598 650 8230 0 0 link
28.02.2024 29.02.2024 Parsey Merdad
Chief Medical Officer		 Sale 73.18 146 360 2000 0 0 link
16.01.2024 17.01.2024 Dickinson Andrew D
Chief Financial Officer		 Sale 85.78 428 900 5000 0 0 link
09.01.2024 10.01.2024 Mercier Johanna
Chief Commercial Officer		 Sale 85.23 702 466 8242 0 0 link
20.07.2023 21.07.2023 Dickinson Andrew D
Chief Financial Officer		 Sale 80 400 000 5000 0 0 link
01.02.2022 02.02.2022 Pletcher Brett A
EVP,Corp Affairs & Gen Counsel		 Sale 68.54 963 741 14061 0 0 link

Institutions Volume Share, %
Blackrock Inc. 122793011 9.86
Vanguard Group Inc 111822428 8.98
Capital World Investors 83364123 6.7
Capital Research Global Investors 59657126 4.79
State Street Corporation 59536425 4.78
Dodge & Cox Inc 33295023 2.67
Geode Capital Management, LLC 25274185 2.03
Wellington Management Group, LLP 18630134 1.5
Morgan Stanley 17801718 1.43
FMR, LLC 17097648 1.37

ETF Share, % Profitability for 1 year, % Dividends, %
Future Tech ETF 8.5029 426.34 0.8416
Principal Healthcare Innovators ETF 8.5029 618.5 0.8416
iShares Evolved U.S. Innovative Healthcare ETF 4.1 0.000586 2.79
Pacer BioThreat Strategy ETF 3.56666 15.84 1.65371
2nd Vote Life Neutral Plus ETF 3.36 0 1.86
Donoghue Forlines Innovation ETF 1.90015 10.06 0.89556
John Hancock Multifactor Healthcare ETF 1.62 29.34 1.62
FCF US Quality ETF 1.49429 18.99 1.58997
Nationwide Maximum Diversification U.S. Core Equity ETF 1.3 26.65 1.58
VanEck Morningstar Global Wide Moat ETF 1.0755 58.27 2.44324
Nationwide Nasdaq-100 Risk-Managed Income ETF 0.71563 21.38 0.87606
JPMorgan Corporate Bond Research Enhanced ETF 0.41 6.26 4.16
iShares Morningstar Large-Cap Value ETF 0.40345 63.82 2.17567
Columbia U.S. ESG Equity Income ETF 0.3637 -99.18 1.44131
iShares Morningstar Large-Cap ETF 0.20825 257.57 1.41244



Head Job title Payment Year of birth
Mr. Andrew D. Dickinson Chief Financial Officer 2.66M 1970 (55 years)
Ms. Johanna Mercier Chief Commercial Officer 3.1M 1970 (55 years)
Dr. Merdad V. Parsey M.D., Ph.D. Chief Medical Officer 2.79M 1963 (62 years)
Ms. Jacquie Ross C.F.A. Vice President of Investor Relations N/A
Ms. Jyoti K. Mehra Executive Vice President of Human Resources N/A 1977 (48 years)
Dr. Linda Slanec Higgins Ph.D. Senior Vice President of Research, Innovation & Portfolio N/A 1962 (63 years)
Ms. Sandra Patterson Senior VP, Corporate Controller & Principal Accounting Officer N/A 1967 (58 years)
Dr. Rudolf Ertl Senior Vice President of Commercial Operations of Australia, Canada, Europe N/A 1946 (79 years)
Mr. Daniel P. O'Day Chairman & CEO 1964 (61 year)
Ms. Deborah H. Telman Executive VP of Corporate Affairs, General Counsel & Corporate Secretary 1965 (60 years)

Address: United States, Foster City, 333 Lakeside Drive - open in Google maps, open in Yandex maps
Website: http://www.gilead.com